PDS Biotech Announces Agreement with University of Georgia to License New Proteins for Versamune-Based Universal Influenza Vaccine
FLORHAM PARK, NJ, November 01, 2021 (GLOBE NEWSWIRE) – PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on Versamune Company ownerÂ® T cell activation technology, announced today a license agreement for COBRA (Computational Optimized Widely Reactive Antigen) antigens from the University of Georgia initially for use in the clinical development of its immunotherapy pipeline of infectious diseases, PDS0202, a universal vaccine candidate against influenza.
âOur new agreement with the University of Georgia demonstrates the versatility and potential of our VersamuneÂ® platform and advance our infectious disease pipeline, âcommented Frank Bedu-Addo, CEO of PDS Biotech. âThere are four types of seasonal influenza viruses, and a universal influenza vaccine would eliminate the need to manufacture a new seasonal influenza vaccine each year by providing robust and long-lasting protection against several influenza subtypes. We believe this is the next step in advancing new infectious disease vaccines to treat nearly one billion cases of influenza globally each year. “
Developed by renowned influenza expert Dr. Ted Ross of the University of Georgia, the new COBRA antigens are to be used in conjunction with VersamuneÂ® for PDS0202 for the universal prevention of infection with multiple strains of influenza virus. The antigens were selected following successful preclinical development work under a contract from the National Institute of Allergy and Infectious Diseases (NIAID), Collaborative Influenza Vaccine Innovation Centers (CIVIC) program to make advance the development of PDS0202. PDS0202 uses VersamuneÂ®ability of the immune system to generate high levels of influenza-specific neutralizing antibodies, CD4 helper and CD8 killer T cells, as well as long-acting memory T cells to potentially provide broad and long-term protection against several influenza strains . It is estimated that influenza causes about 3 to 5 million cases of serious illness and about 290,000 to 650,000 respiratory deaths worldwide each year.
“The preclinical results of the combination of COBRA and Versamune antigensÂ® were impressive, especially given the unique challenge of developing a universal influenza vaccine, âadded Dr. Ross. âThe goal is to design a vaccine that works for many strains of influenza. We are excited to see how the PDS0202 – COBRA vaccine performs in human trials. “
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing portfolio of cancer immunotherapies based on the Company’s proprietary product, Versamune.Â® Technological platform for T cell activation. Our VersamuneÂ®These products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing large amounts of high quality and very potent tumor-specific polyfunctional CD4 + helper and CD8 + killer T cells in vivo. PDS Biotech has developed multiple therapies, based on combinations of VersamuneÂ® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and to attack and destroy them effectively. The company’s pipeline products treat a variety of cancers, including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended. ) regarding PDS Biotechnology Corporation (the âCompanyâ) and other matters. These statements may discuss objectives, intentions and expectations regarding future plans, trends, events, results of operations or financial condition, or otherwise, based on the current beliefs of the management of the Company, as well as assumptions made by and information currently available for management. Forward-looking statements generally include statements that are predictive in nature and depend on or refer to future events or conditions, and include words such as “may”, “will”, “should”, “would expect”, ” expect “,” anticipate “,” plan “,” likely “,” believe “,” estimate “,” project “,” intend “,” forecast “,” direction “,” prospect “and other similar expressions, among others. Forward-looking statements are based on current beliefs and assumptions which are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement due to various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital needs, including the Company’s anticipated cash flow path and the Company’s current expectations regarding its future equity financing plans; the dependence of the Company on additional financing to finance its operations and complete the development and commercialization of its product candidates, and the risks that the raising of this additional capital could restrict the operations of the Company or oblige the Company to waive its rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to assess the Company’s outlook, the Company’s business plan or the likelihood of implementation. successful implementation of such a business plan by the Company; the schedule for the Company or its partners to initiate the clinical trials planned for PDS0101, PDS0203 and other VersamuneÂ® products based on products; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaborative studies regarding PDS0101, PDS0203 and other VersamuneÂ® products based on the products and the interpretation of the Company or supervisory committees or other third parties of the results and conclusions of such programs and collaborations and whether these results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and planned clinical trials for the Company’s current product candidates, including statements regarding start-up schedule, pace of recruitment, significance of milestones and the completion of trials (including our ability to fully fund our disclosed clinical trials, which assume no material changes from our currently projected spending), futility analyzes, conference presentations and reported data in a summary, and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials activities; any statement by the Company concerning its understanding of the mechanisms of action of product candidates and the interpretation of the preclinical and early clinical results of its clinical development programs and any collaborative studies; market acceptance of the Company’s product candidates, if approved; the timing and ability of the Company to obtain and maintain the approval of the United States Food and Drug Administration or other regulatory authority, or other actions regarding the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments which are beyond the Company’s control, including unforeseen circumstances or other disruptions to normal business operations resulting from or related to COVID-19. The foregoing consideration of material factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with the statements which are included herein and elsewhere, including the factors of risk included in the Company’s annual and periodic reports filed with the latter. Forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company assumes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statement, whether as a result of new information, future events or otherwise.
Media contact and investor relations:
Telephone: +1 (908) 517-3613
E-mail: [email protected]
Telephone: +1 (404) 736-3838
E-mail: [email protected]